Study to Compare the Effects of Rituximab Compared to Mycophenolate Mofetil (MMF) on Pemphigus Vulgaris

What we are studying

The purpose of this study is to compare the effects, good or bad, of Rituximab with another drug called mycophenolate mofetil (MMF) in treating patients with pemphigus vulgaris. Both drugs have been available worldwide for over 15 years to treat other diseases; however, none of them have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of pemphigus vulgaris.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • Hispanic or Latino
  • Ages 18+

Eligibility Criteria

  • Must have previous biopsy showing pemphigus vulgaris

What is involved

  • Physical Exam
  • Urine pregnancy tests
  • Vital signs
  • ECG
  • Chest x-ray
  • Blood draws
  • CRU visits
  • Four IV infusions

Compensation

$1,360/$50 per visit and $190 per visit on infusion days

Contact Information

Study Coordinator
Dermatology Clinical Studies
Email
dermadvertising@wakehealth.edu
Phone
336-716-3775

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.